Vivozon Secures Patents for Non-Narcotic Analgesic 'VVZ-2471' in Korea and Israel
Vivozon, an affiliate of Vivozon Pharmaceutical, has secured domestic and Israeli patents for its oral non-narcotic analgesic candidate, 'VVZ-2471'.
According to Vivozon on September 21, the newly granted domestic patent widely recognizes the scope of rights for a core group of compounds, including VVZ-2471. The claims were approved for 125 compounds described at the time of the patent application, ensuring domestic rights for VVZ-2471 and related candidate substances.
Vivozon has expanded the regions where patents are registered to include Korea and Israel, following the United States, China, Taiwan, South Africa, Japan, and Europe. As a result, the regions where related patent rights are secured have increased to a total of eight countries or regions, and patent review is currently underway in Australia, Brazil, Canada, and India.
VVZ-2471 is an oral non-narcotic analgesic candidate that simultaneously inhibits metabotropic glutamate receptor 5 (mGluR5) and serotonin receptor 2A (5-HT2A), which are involved in pain signal transmission. The company is developing it as a first-in-class innovative drug designed to address the addiction and tolerance issues associated with existing opioid analgesics.
Clinical development is also underway. In Korea, dosing for a Phase 2 clinical trial targeting patients with postherpetic neuralgia (PHN) was recently completed. In the United States, an investigator-initiated trial (IIT) is ongoing in collaboration with local research institutes, based on Investigational New Drug (IND) approval.
Hot Picks Today
"I Ate at Home to Save Money, But My Account Balance Was Still a Shock"
- Suddenly Called Out During Class, Awarded $100,000 as Students Cheer in the Gym
- "Bought It Cheaper in Japan Than Korea"... Improper Use Leads to Vomiting and Abdominal Pain, Official Warning Issued
- "After a Dream About Feces, Bought a Lottery Ticket and Won 20,000 Won... Scratched Again and Hit a 2 Billion Won Jackpot"
- "Uncle Will Buy Them All for Wonie"... Men in Their 30s Sweep Up 600,000 'RESCENE Bread'
A Vivozon representative stated, "By successively acquiring patent rights in Korea and Israel, we have strengthened the global intellectual property foundation of VVZ-2471," adding, "We will ensure the smooth progress of the domestic Phase 2 trial and investigator-initiated clinical studies in the United States to accelerate the drug's global commercialization."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
